Clinical Trials Sponsored by Quotient Sciences

Total 19390 results

Gilead Sciences

Completed

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Solid Tumor

United States
Gilead Sciences

Completed

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

Canada, United States, Hong Kong, United Kingdom, Switzerland, New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Hepatitis C Virus Infection

Singapore, Vietnam, China, Thailand, Malaysia
Gilead Sciences

Completed

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus (RSV)

United States, Belgium, Canada, Netherlands, Australia, Germany, United Kingdom, France
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

Spain
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, France, Spain, Poland, United Kingdom, Australia, Belgium, Canada
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

Belgium, Austria, New Zealand, United Kingdom, Germany, Spain, Netherlands, France, Switzerland, Canada, Australia, Italy
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, Spain, Switzerland, Canada, Thailand, Puerto Rico, Australia, Austria, Belgium, Italy, Japan, United Kingdom
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

HCV Infection

United States, France, Australia, Puerto Rico, Spain
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion

United States, Spain, Denmark, Belgium, Australia, Poland, Romania, Czechia, Italy, France, Hungary, Austria, Portugal, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

HIV

United States, South Africa
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (Yosemite)

Indolent Non-Hodgkin's Lymphomas

United States, Korea, Republic of, Hungary, United Kingdom, Australia, Singapore, Japan, Taiwan, Israel, Italy, Spain, Czechia, Russian Federation, France, Poland, Romania, Germany, Portugal, Sweden
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

HIV | Hepatitis C Virus

United States, New Zealand, Canada, Puerto Rico
Gilead Sciences

Terminated

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Hepatitis C Virus Infection

United States, Canada, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Hepatitis C Virus Infection

Russian Federation, Sweden
Gilead Sciences

Completed

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

HIV | HBV

United States, Canada, Japan
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
Gilead Sciences

Completed

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV

United States, Thailand, Uganda, Dominican Republic, Russian Federation
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

Hepatitis C

United States, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection (ASTRAL-1)

Hepatitis C Virus Infection

United States, France, Canada, Germany, Puerto Rico, United Kingdom, Belgium, Italy, China
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Gilead Sciences

Completed

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

Chronic Hepatitis B

Canada, United States, United Kingdom, Australia, New Zealand
Parion Sciences

Terminated

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Gilead Sciences

Completed

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

HCV Infection

Mexico
Gilead Sciences

Completed

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Infection

Korea, Republic of, Australia, Israel, New Zealand, Netherlands, United States, France, United Kingdom, Italy, Belgium, Poland
Gilead Sciences

Terminated

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Cystic Fibrosis

France, Germany, Spain, United Kingdom, Australia
Gilead Sciences

Terminated

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, Spain, Uganda, South Africa, Italy
Gilead Sciences

Terminated

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Gilead Sciences

Completed

Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States

Chronic Hepatitis B

United States
Gilead Sciences

Terminated

Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) (ATLAS)

Idiopathic Pulmonary Fibrosis

United States
Gilead Sciences

Completed

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

Chronic Hepatitis B

France, Canada, Spain, Germany, Italy, United States, New Zealand, Australia, Czech Republic, Bulgaria, Turkey, Poland, Greece, Netherlands, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection

Chronic HCV Infection

India
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Hepatitis C | Cirrhosis | Portal Hypertension | With or Without Liver Decompensation

United States, Spain, New Zealand, Australia, France
Gilead Sciences

Completed

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

Hepatitis B Virus (HBV)

Turkey, United States, Romania, France, Poland, Bulgaria, Spain
Gilead Sciences

Completed

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Hong Kong, Spain, Taiwan, United States, Poland, France, Netherlands, Singapore, Australia, Canada, Italy, United Kingdom, Germany, Portugal, Romania, Greece, Turkey, India
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

Canada, Switzerland, United States, France, Spain, Germany, Belgium, Austria, Italy, United Kingdom, Puerto Rico, Portugal
Gilead Sciences

Completed

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, Spain, Puerto Rico, Australia, Thailand, Brazil, France, Belgium, Canada, Dominican Republic, United Kingdom, Germany, Netherlands, Italy, Austria, Denmark, Mexico, Portugal, Switzerland
Gilead Sciences

Completed

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Puerto Rico
Gilead Sciences

Completed

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Hepatitis B

Canada, Germany, Turkey, United States, Greece, New Zealand, Hungary, Romania, Bulgaria, Serbia, Austria, Poland, Czech Republic, Spain
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
Gilead Sciences

Completed

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Chronic Hepatitis B

Taiwan, France, Germany, Hong Kong, United States, Canada, New Zealand, Australia, Singapore, Poland, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy

HIV Infections

Brazil, Panama
Gilead Sciences

Completed

A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Gilead Sciences

Withdrawn

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

Ischemic Heart Disease

3

Subscribe